238 related articles for article (PubMed ID: 20425385)
1. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Mesa RA; Quintás-Cardama A; Verstovsek S
Curr Hematol Malig Rep; 2007 Feb; 2(1):25-33. PubMed ID: 20425385
[TBL] [Abstract][Full Text] [Related]
2. Experimental therapy in myelofibrosis with myeloid metaplasia.
Verstovsek S; Quintás-Cardama A; Kantarjian H; Tefferi A
Expert Opin Investig Drugs; 2006 Dec; 15(12):1555-63. PubMed ID: 17107281
[TBL] [Abstract][Full Text] [Related]
3. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
4. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
5. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
[TBL] [Abstract][Full Text] [Related]
6. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
Mesa RA
Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
[TBL] [Abstract][Full Text] [Related]
7. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Tefferi A; Barosi G; Mesa RA; Cervantes F; Deeg HJ; Reilly JT; Verstovsek S; Dupriez B; Silver RT; Odenike O; Cortes J; Wadleigh M; Solberg LA; Camoriano JK; Gisslinger H; Noel P; Thiele J; Vardiman JW; Hoffman R; Cross NC; Gilliland DG; Kantarjian H;
Blood; 2006 Sep; 108(5):1497-503. PubMed ID: 16675707
[TBL] [Abstract][Full Text] [Related]
8. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.
Hogan WJ; Litzow MR; Tefferi A
Curr Hematol Malig Rep; 2007 Feb; 2(1):34-42. PubMed ID: 20425386
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
11. Erythroleukemia following erythropoietin therapy, extramedullary hematopoiesis, and splenectomy in a patient with myelofibrosis and myeloid metaplasia.
Coleman TA; Hamill RL; Ford SM
Am J Hematol; 2001 Jul; 67(3):214-5. PubMed ID: 11391725
[No Abstract] [Full Text] [Related]
12. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
13. New insights into the pathogenesis and drug treatment of myelofibrosis.
Tefferi A
Curr Opin Hematol; 2006 Mar; 13(2):87-92. PubMed ID: 16456374
[TBL] [Abstract][Full Text] [Related]
14. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
[TBL] [Abstract][Full Text] [Related]
15. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi A
Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
[TBL] [Abstract][Full Text] [Related]
16. Investigational Janus kinase inhibitors in development for myelofibrosis.
Bose P; Abou Zahr A; Verstovsek S
Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Harrison C; Verstovsek S; McMullin MF; Mesa R
Br J Haematol; 2012 May; 157(4):426-37. PubMed ID: 22463737
[TBL] [Abstract][Full Text] [Related]
18. The therapy of myelofibrosis: targeting pathogenesis.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
[TBL] [Abstract][Full Text] [Related]
19. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
Barba P; Fox ML; Blanco A; Valcárcel D
Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
[No Abstract] [Full Text] [Related]
20. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
Tefferi A; Strand JJ; Lasho TL; Elliott MA; Li CY; Mesa RA; Dewald GW
Cancer; 2006 Apr; 106(8):1739-43. PubMed ID: 16532437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
